Hydrogel nanoparticles used as injectable subcutaneous implant agent

Abstract

The invention relates to hydrogel nanoparticles used as an injectable subcutaneous implant agent, which can effectively solves the problem of fulfilling an aim of realizing tumor treatment by locally injecting the hydrogel nanoparticles beside a subcutaneous tumor, changing the hydrogel nanoparticles into a gel and slowly releasing nanoparticles in vivo. The hydrogel nanoparticles are prepared from hydrogel solution and 2-methoxyl estradiol liposome nanoparticle powder or solid liposome nanoparticle powder by a method which comprises the following steps of: adding the 2-methoxyl estradiol liposome nanoparticle powder or the solid liposome nanoparticle powder into the hydrogel solution; and uniformly mixing to form the hydrogel nanoparticles which can be used as an injectable subcutaneous implant agent, wherein 100mg of the 2-methoxyl estradiol liposome nanoparticle powder is added into every 1ml of the hydrogel solution. The injectable hydrogel implant agent of the invention can be used for treating subcutaneous tumors such as breast cancer and the like, keep an effective medicament concentration in a local target site, can realize sustained release and controlled release, can avoid medicament resistance caused by long-term medication, simultaneously improve a curative effect and reduce dosage, reduce toxic and side effects on a whole body, and also can prevent lymphatic metastasis of the tumors such as the breast cancer and the like.

Description

1. Technical field [0001] The invention relates to medicine, in particular to a nanoparticle hydrogel used as an injectable subcutaneous implant. 2. Background technology [0002] Implants for subcutaneous tumor therapy are currently generally in the form of solids that require minor surgery to implant subcutaneously for efficacy or locally injectable suspensions of microspheres. The former implant has poor patient compliance, while the latter has high patient compliance, but its preparation process is more complicated, and toxic organic solvents may be used in the preparation process, resulting in organic solvent residues, and it only releases the original drug to the target. parts function. However, since breast cancer and other subcutaneous tumors usually require long-term medication, it is easy to develop drug resistance; some anticancer drugs are more toxic, and when they produce high local concentrations, they will also cause high blood drug concentrations, so that th...

AI Technical Summary

Problems solved by technology

The former implant has poor patient compliance, while the latter has high patient compliance, but its preparation process is more complicated, and toxic organic solvents may be used in the preparation process, resulting in organic solvent residues, and it only releases the original drug to the target. parts play a role

However, since breast cancer and other subcutaneous tumors usually require long-term medication, it is easy to develop drug resistance; some anticancer drugs are more toxic, and when they produce high local concentrations, they will also cause high blood drug concentrations, so that the drugs are distributed throughout the body and cause Toxicity; some anticancer drugs target cells inside the cells. For these anticancer drugs, the above two implants are prepared, and the efficacy or toxicity is difficult to guarantee

Images